The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
 
Jie Wang
No Relationships to Disclose
 
Zhijie Wang
No Relationships to Disclose
 
Lin Wu
Employment - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Hengrui Pharmaceutical ; Innovent Biologics; Lilly; Merck; MSD; Pfizer; Roche
 
Baolan Li
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Xiaoling Li
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Liang Han
No Relationships to Disclose
 
Xiaohong Wu
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Dongqing Lv
No Relationships to Disclose
 
Jianhua Shi
Honoraria - BeiGene; Roche
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Jianjin Huang
No Relationships to Disclose
 
Shaozhang Zhou
No Relationships to Disclose
 
Baohui Han
No Relationships to Disclose
 
Guogui Sun
No Relationships to Disclose
 
Qisen Guo
No Relationships to Disclose
 
Youxin Ji
No Relationships to Disclose
 
Xiaoli Zhu
No Relationships to Disclose